Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
about
Direct renin inhibitors for preventing the progression of diabetic kidney diseaseAvosentan reduces albumin excretion in diabetics with macroalbuminuriaSupramaximal dose of candesartan in proteinuric renal diseaseInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemMonitoring kidney function and albuminuria in patients with diabetes.Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?Can you trust your animal study data?Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.Correlation between albuminuria and spontaneous platelet microaggregate formation in type 2 diabetic patientsAssociation between urinary albumin excretion and intraocular pressure in type 2 diabetic patients without renal impairment.Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney diseaseAutomating and estimating glomerular filtration rate for dosing medications and staging chronic kidney disease.Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease.Diminished renal function and the incidence of heart failure.Proteinuria, (99m) Tc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease.Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaAssociation of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004).Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Predicting the outcome of chronic kidney disease by the estimated nephron number: the rationale and design of PRONEP, a prospective, multicenter, observational cohort study.Renal protection in diabetes: lessons from ONTARGET.Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.Association of the estimated 24-h urinary sodium excretion with albuminuria in adult koreans: the 2011 Korea National Health and Nutrition Examination SurveyEffects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.End organ damage in hypertension.Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease.Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).Serum gamma - glutamyltransferase is associated with albuminuria: a population-based studyImpact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials.Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney diseaseAliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Improving prognosis estimation in patients with heart failure and the cardiorenal syndromeRole of aliskiren in blood pressure control and renoprotectionHigh-normal albuminuria and risk of heart failure in the community.Changes in albuminuria predict mortality and morbidity in patients with vascular diseaseDevelopment and validation of a self-assessment tool for albuminuria: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.Cause-specific mortality according to urine albumin creatinine ratio in the general population.Slowing nephropathy progression: focus on proteinuria reduction.
P2860
Q24198989-8B1AA472-C63A-416B-9374-2AB7EE241C4FQ24642372-36259C0B-046C-434E-8D16-A35055522A82Q24649685-FE2F124C-1EDD-437A-9189-F2205562EC13Q26822500-2869888E-B73F-4A78-9909-10DD965C7147Q27691297-4D30094C-B660-405B-AE67-1B0B23D2C7CCQ28219261-1EE04165-9D57-4793-8509-DAF8031AAD2DQ30829341-DE668BCE-CB28-4FA1-8ED7-C6BAC81F34F9Q30961976-97F40D6E-4D93-4A3E-AFDB-B56AF2396EE2Q33493041-688CAA23-DCF4-4802-92E5-997B45B8C680Q33560508-A020D016-0154-44C6-A9EC-AB82D7F5667EQ33576711-EF3AAB98-9BD2-46E9-A005-A6628EC8A5F0Q33583503-F0DB50FF-86EB-4E15-A296-FEFCEBCAA080Q33642939-7CA48A6E-9462-4559-9237-496FC1885ECFQ33654021-FF72587A-18A8-49F9-A7AE-D0B4FBFCD1AAQ33710875-E81E4919-C807-4D85-ACC2-22D7D57B1F93Q33735287-6D2E851F-B0CB-4E55-88E8-38837A9DD74EQ33764038-73536AAA-CE16-487D-A529-226B3C3327B9Q33776181-01D0FFD6-A37B-4F2A-A4B1-3DA3C6B979D2Q33984240-AB2F4F6A-939A-4669-8066-337A9E546ECBQ34190377-EC3556AF-5651-444F-A9A7-05FCBD55B44FQ34221460-34BE9530-D18D-42DC-8C62-69A9B888B164Q34237280-28FEADFE-EC0E-47C5-8B07-BB53521F3837Q34337479-7541A651-F653-4433-8239-EEDE0C44D5B0Q34405404-72AFDE66-ED50-4B99-9DAC-2F131BC80974Q34444944-E7EB8E7D-2DAC-4D9B-91B6-B166773577BDQ34483554-1710AE3E-5EAF-49AA-93FA-02D8D514AA26Q34612908-28FBC4C8-B415-4DC9-9D9C-70351D13301BQ34627724-C87E44C3-5DA7-42D4-A34D-8811FCC5CDE3Q34681908-00D2B262-B9BB-43A0-98A4-556A82A5840CQ34692107-3EBE149E-09E6-429A-B3CE-B3B622451E48Q34726905-38932E26-B222-4AC6-94E1-35F0AE507949Q34788186-30DD3E14-8A08-4EF5-95D4-D19FAF9CE513Q34926825-E18B3D1F-26D3-4B67-B8C2-1EBFF1E09D09Q35020305-D8F707CA-B94F-4141-B050-2D9394C9911CQ35026735-AE154D3D-CBC9-4119-88B7-06AE9B670FFEQ35058809-39A2F2BE-CFD5-42B9-B096-E78EDA335F99Q35108899-DA362257-B5CD-4464-8517-6533AFC46AB5Q35129851-87BCFAB9-2233-4363-9915-12A9A466763AQ35133466-BC6236ED-79BA-4360-BDEC-0C876B6C0F42Q35153298-60F84A35-E2EA-42E2-BED4-E32C9236BE29
P2860
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@en
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@nl
type
label
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@en
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@nl
prefLabel
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@en
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@nl
P2093
P1433
P1476
Albuminuria, a therapeutic tar ...... tic patients with nephropathy.
@en
P2093
Barry M Brenner
Dick de Zeeuw
Hans-Henrik Parving
Mark E Cooper
Shahnaz Shahinfar
Steve Snapinn
William E Mitch
William F Keane
Zhongxin Zhang
P304
P356
10.1161/01.CIR.0000139860.33974.28
P407
P577
2004-08-09T00:00:00Z